Aclaris Therapeutics
ACRS
128 hedge funds and large institutions have $980M invested in Aclaris Therapeutics in 2021 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 18 closing their positions.
172% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 18
32% more funds holding
Funds holding: 97 → 128 (+31)
15% more call options, than puts
Call options by funds: $3.32M | Put options by funds: $2.88M
7% more ownership
Funds ownership: 87.68% → 94.68% (+7%)
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
14% less capital invested
Capital invested by funds: $1.14B → $980M (-$165M)
47% less funds holding in top 10
Funds holding in top 10: 15 → 8 (-7)
Top Buyers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$87.8M |
| 2 |
BlackRock
New York
|
+$51.2M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$22.7M |
| 4 |
State Street
Boston,
Massachusetts
|
+$19.9M |
| 5 |
Holocene Advisors
New York
|
+$19.8M |
Top Sellers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$27.3M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$20.2M |
| 3 |
Renaissance Technologies
New York
|
-$12.6M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$8.54M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$7.95M |
ACRS Hedge Fund Activity: Q2 2021 in Review
128 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q2 2021, worth a combined $980M — down 14% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ACRS positions and 18 closed out — a net gain of 31 holders — while 34 added to existing stakes and 32 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $87.8M. The largest seller was Adage Capital Partners, cutting an estimated $27.3M.
- 128 institutional investors held Aclaris Therapeutics (ACRS) as of Q2 2021, up from 97 in Q1 2021.
- Funds reported $980M of Aclaris Therapeutics stock for Q2 2021, down 14% quarter-over-quarter.
- 49 funds opened new Aclaris Therapeutics positions in Q2 2021 and 18 closed out, a net change of +31 holders.
- The largest Aclaris Therapeutics buyer in Q2 2021 was Wellington Management Group, an estimated $87.8M added.
- The largest Aclaris Therapeutics seller in Q2 2021 was Adage Capital Partners, an estimated $27.3M sold.
Based on aggregated 13F filings for Q2 2021.